Alume Biosciences Raises $13M in Series B Funding
Summary
Alume Biosciences, a La Jolla, CA-based company in the field of nerve-targeted diagnostics and therapeutics, raised $13M in Series B funding. The company intends to use the funds to advance its lead candidate, Bevonescein (ALM-488), in Phase 3 clinical trials. Led by CEO Quyen Nguyen, Alume Biosciences is a late-stage clinical biotechnology company developing nerve specific targeting molecules. ALM-488 is a proprietary fluorescent peptide-dye conjugate in the visible spectrum and can be visualized with fluorescently enabled instrumentation including filter modified loupe systems, portable handheld systems, microscopes and laparoscopes. In addition to ALM-488, the company is developing other nerve specific agents for diagnostic and therapeutic indications.